Integrating transcriptomics with metabolic modeling predicts biomarkers
and drug targets for Alzheimer's disease
(S. Stempler, K. Yizhak, E. Ruppin)
PLoS One, in press.
Network-level architecture and the evolutionary potential of underground
(R.A. Notebaart, B. Szappanos, B. Kinteses, F. Pal, A. Gyorkei,
B. Bogos, V. Lazar, R. Spohn, A. Wagner, E. Ruppin, C. Pal, B. Papp)
Proceedings of the National Academy of Sciences (PNAS), in press.
A computational study of the Warburg effect identifies metabolic targets
inhibiting cancer migration
(K. Yizhak*, S. E. Devedec*, V.M. Rogkoti, F. Baenke, V.C. de Boer, C. Frezza,
A. Schulze, B. van de Water#, E. Ruppin#)
(first author equal contribution *,
last author equal contribution #).
Molecular Systems Biology (MSB), in press.
Glycan Degradation (GlyDer) analysis predicts mammalian gut
microbiota abundance and host diet-specific adaptations
(O. Eilam, R. Zarecky, M. Oberhardt, L.K. Ursell, M. Kupiec, R. Knight,
U. Gophna, E. Ruppin)
mBio, in press.
Predicting cancer-specific vulnerability via data-driven detection of
(L. Jerby-Arnon, N. Pfetzer, Y.Y. Yaldman, L. McGarry, D. James,
E. Shanks, B. Seashore-Ludlow, A. Weinstock, T. Geiger, P.A. Clemons,
E. Gottlieb, E. Ruppin)
Cell, in press.
Combining drug and gene similarity metrics for drug-target elucidation
(L. Perlman, A. Gottlieb, N. Atias, E. Ruppin, R. Sharan)
Journal of Computational Biology (JCB), to appear.
A novel HMM-based method for detecting enriched transcription
factor binding sites reveals RUNX3 as a potential target in pancreatic
(L. Levkovitz, N. Yosef, M.C. Gershgoren, E. Ruppin, R. Sharan, Y. Oron)
PLoS One, to appear.